FDA Clears CT-Based AI Tools for PE Detection and Stroke Severity Assessment
The artificial intelligence (AI) modalities CINA-iPE and CINA-ASPECTS may facilitate improved detection of incidental pulmonary embolism and stroke evaluation, respectively, based on computed tomography (CT) scans.
The Food and Drug Administration (FDA) has granted 510(k) clearance to the artificial intelligence (AI)-powered CINA-ASPECTS, which may enhance the evaluation of stroke severity, and the AI-enabled CINA-IPE, which is geared toward bolstering the detection of incidental pulmonary embolism (PE).
Based off brain non-contrast computed tomography (NCCT) images, the CINA-ASPECTS modality provides heat mapping probabilities of sulcal effacement and hypodensity, identifies infarcted regions and offers automated ASPECT scoring for stroke severity, according to Avicenna.AI, the developer of CINA-ASPECTS.
The newly FDA-cleared CINA-ASPECTS reportedly provides automated ASPECTS scoring of stroke severity based off of non-contrast CT scans of the brain, according to Avicenna.AI. (Photo courtesty of Avicenna.AI.)
"The validations and multi-reader-multi-case studies we conducted highlighted that CINA-ASPECTS not only obtained outstanding standalone performance, but also demonstrated that its adjunctive use significantly improved clinicians' accuracy in the assessment of ASPECTS regions, compared to the conventional use of NCCT images alone," added Yasmina Chaibi, a clinical affairs manager for Avicenna.AI.
Avicenna.AI said the CINA-iPE modality, reportedly validated on 381 CT scans from 39 different CT scanner models, may facilitate timely triage with its strong sensitivity and specificity for the diagnosis of incidental PE.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
